Injexate

Methotrexate, the active ingredient in Injexate, is an antimetabolite (folate antagonist) presented as a sterile solution for subcutaneous use. It is employed to treat rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma and other malignancies that respond to methotrexate therapy.

GNH USA supplies Injexate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across several disease families, primarily inflammatory and malignant conditions.

- Rheumatoid arthritis: reduces disease activity and joint inflammation in adult patients. - Psoriasis: improves skin lesions and slows disease progression. - Acute lymphoblastic leukemia: induces remission by targeting rapidly dividing leukemic cells. - Non‑Hodgkin lymphoma: contributes to tumor control as part of combination regimens. - Other malignancies responsive to methotrexate: provides cytotoxic effect in various solid tumours and hematologic cancers.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration (mouth sores). - Transient elevation of liver enzymes. - Mild rash or itching. - Decreased white blood cell count.

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis. - Pulmonary toxicity, including interstitial pneumonitis. - Life‑threatening infection due to bone‑marrow suppression. - Acute renal failure. - Severe cutaneous adverse reactions (e.g., Stevens‑Johnson syndrome). - Bone‑marrow aplasia leading to pancytopenia.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks. - Monitor liver function: perform periodic liver enzyme tests. - Monitor blood counts: check complete blood count regularly. - Assess renal function: evaluate serum creatinine and adjust dose if needed. - Avoid use in pregnancy: methotrexate is teratogenic and contraindicated. - Review concomitant nephrotoxic or hepatotoxic drugs: adjust therapy to reduce cumulative toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that may alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Azathioprine: enhanced myelosuppression when combined. - Phenytoin: may reduce methotrexate plasma concentrations. - Folic acid supplements: can diminish therapeutic effect if not timed appropriately.